Equity research analysts and institutional forecasting models covering Orchid Pharma project a consensus 12-month target price hovering around 913 to 976 rupees, with upper analyst estimates reaching up to 1,061 rupees per share. These projections are driven by anticipated revenue expansion across domestic formulations and export markets, though analysts continually adjust targets based on quarterly net income variations and industry margin fluctuations.